171 related articles for article (PubMed ID: 34331670)
21. Study of Caspase 8 Inhibition for the Management of Alzheimer's Disease: A Molecular Docking and Dynamics Simulation.
Ahmad SS; Sinha M; Ahmad K; Khalid M; Choi I
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365525
[TBL] [Abstract][Full Text] [Related]
22.
Teli MK; Kumar S; Yadav DK; Kim MH
J Biomol Struct Dyn; 2021 Feb; 39(2):703-717. PubMed ID: 31914862
[TBL] [Abstract][Full Text] [Related]
23. Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays.
Sahin K; Zengin Kurt B; Sonmez F; Durdagi S
J Biomol Struct Dyn; 2020 Jul; 38(11):3342-3358. PubMed ID: 31462153
[TBL] [Abstract][Full Text] [Related]
24. Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.
Martinez AN; Philipp MT
J Neurol Neuromedicine; 2016; 1(2):29-36. PubMed ID: 27430034
[TBL] [Abstract][Full Text] [Related]
25. Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking.
Langeswaran K; Jeyaraman J; R JB; Biswas A; Dhurgadevi KR
J Recept Signal Transduct Res; 2019 Apr; 39(2):99-105. PubMed ID: 31282287
[TBL] [Abstract][Full Text] [Related]
26.
Sahin K
J Biomol Struct Dyn; 2022 Feb; 40(3):1152-1162. PubMed ID: 33016840
[TBL] [Abstract][Full Text] [Related]
27. In-silico and in-vitro evaluation of human acetylcholinesterase inhibition by organophosphates.
Ranjan A; Chauhan A; Jindal T
Environ Toxicol Pharmacol; 2018 Jan; 57():131-140. PubMed ID: 29272792
[TBL] [Abstract][Full Text] [Related]
28. An in silico approach to discover the best molecular modeling strategy for designing novel CDK4 inhibitors.
Vasanthakumari D; Vadakkethil Lalithabhai P; Kanthimathi Bahuleyan M
Chem Biol Drug Des; 2019 Apr; 93(4):556-569. PubMed ID: 30536727
[TBL] [Abstract][Full Text] [Related]
29. Identifying novel inhibitor of quorum sensing transcriptional regulator (SdiA) of
Ahmed MZ; Muteeb G; Khan S; Alqahtani AS; Somvanshi P; Alqahtani MS; Ameta KL; Haque S
J Biomol Struct Dyn; 2021 Jul; 39(10):3594-3604. PubMed ID: 32401149
[TBL] [Abstract][Full Text] [Related]
30. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.
Devi B; Jangid K; Kumar N; Kumar V; Kumar V
Mol Divers; 2024 Apr; ():. PubMed ID: 38573427
[TBL] [Abstract][Full Text] [Related]
32. Avanafil mediated dual inhibition of IKKβ and TNFR1 in an experimental paradigm of Alzheimer's disease:
Chowdari Gurram P; Satarker S; Kumar G; Begum F; Mehta C; Nayak U; Mudgal J; Arora D; Nampoothiri M
J Biomol Struct Dyn; 2023 Dec; 41(20):10659-10677. PubMed ID: 36533331
[TBL] [Abstract][Full Text] [Related]
33. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel acetylcholinesterase inhibitors through 3D-QSAR, molecular docking, and molecular dynamics simulation targeting Alzheimer's disease.
El Khatabi K; El-Mernissi R; Aanouz I; Ajana MA; Lakhlifi T; Khan A; Wei DQ; Bouachrine M
J Mol Model; 2021 Sep; 27(10):302. PubMed ID: 34581863
[TBL] [Abstract][Full Text] [Related]
35. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.
Sabe VT; Tolufashe GF; Ibeji CU; Maseko SB; Govender T; Maguire GEM; Lamichhane G; Honarparvar B; Kruger HG
J Mol Model; 2019 Oct; 25(11):328. PubMed ID: 31656981
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel small molecule non-peptidomimetic inhibitor for prolyl oligopeptidase through
Shrivastava A; Srivastava S; Malik R; Alam MM; Shaqiquzamman M; Akhter M
J Biomol Struct Dyn; 2020 Mar; 38(5):1292-1305. PubMed ID: 30929611
[TBL] [Abstract][Full Text] [Related]
37. Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative
Singh R; Ganeshpurkar A; Kumar D; Kumar D; Kumar A; Singh SK
J Biomol Struct Dyn; 2020 Jun; 38(9):2533-2545. PubMed ID: 31232189
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
J Mol Graph Model; 2018 Jan; 79():103-117. PubMed ID: 29156380
[TBL] [Abstract][Full Text] [Related]
39. Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis.
Chadha N; Tiwari AK; Kumar V; Lal S; Milton MD; Mishra AK
J Biomol Struct Dyn; 2015; 33(5):978-90. PubMed ID: 24805972
[TBL] [Abstract][Full Text] [Related]
40. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
